Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company. Already ...

Both AstraZeneca and Roche lifted their respective full-year profit guidances in light of strong quarterly financials released Thursday morning. For AstraZeneca, total revenue increased 17% at ...

Total Revenue up 11% to $43,236m, driven by growth in all Therapy Areas, including 16% growth in Oncology and 13% growth in R&I Growth in Total Revenue across all major geographic regions Core ...

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary Financial performance for H1 2024 (Growth numbers at constant exchange rates) Pascal Soriot, Chief Executive Officer, ...

CAMBRIDGE, England--(BUSINESS WIRE)--Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through ...

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- ...

Corebridge Financial Inc. lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 37,867 shares of the company’s ...

February 2026 AstraZeneca prices a $2bn bond offering AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary AstraZeneca Finance LLC, priced a three tranche global bond offering ...